Karuna Therapeutics Inc.

329.83
0.09 (0.03%)
At close: Mar 15, 2024, 8:00 PM

Company Description

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions.

Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis.

The company also focuses on developing other muscarinic-targeted drug candidates.

Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc.

The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019.

Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Karuna Therapeutics Inc.
Karuna Therapeutics Inc. logo
Country United States
IPO Date Jun 28, 2019
Industry Biotechnology
Sector Healthcare
Employees 339
CEO William Meury

Contact Details

Address:
99 High Street
Boston, Massachusetts
United States
Website https://www.karunatx.com

Stock Details

Ticker Symbol KRTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001771917
CUSIP Number 48576A100
ISIN Number US48576A1007
Employer ID 27-0605902
SIC Code 2834

Key Executives

Name Position
William Meury President, Chief Executive Officer & Director
Jason Parker Brown Chief Financial Officer
Alexis Smith Vice President of Corporate Affairs & Investor Relations
Dr. Alan Breier Chair of Scientific Advisory Board & Chief Clinical Advisor
Dr. Andrew Craig Miller Ph.D. Founder and President of Research & Development
Dr. Ronald N. Marcus M.D. Senior Vice President of Medical
Dr. Stephen K. Brannan Chief Medical Officer
Frank Truslow Senior Vice President of Corporate Development
Jonathan Rosin Chief Human Resources Officer
Mia Kelley J.D. General Counsel

Latest SEC Filings

Date Type Title
Mar 28, 2024 15-12G Filing
Mar 18, 2024 4 Filing
Mar 18, 2024 4 Filing
Mar 18, 2024 4 Filing
Mar 18, 2024 4 Filing
Mar 18, 2024 4 Filing
Mar 18, 2024 4 Filing
Mar 18, 2024 4 Filing
Mar 18, 2024 4 Filing
Mar 18, 2024 4 Filing